Objective: To investigate whether intake of Lactobacillus acidophilus strain L-1 lowers serum cholesterol in healthy men and women. Design: Randomised, placebo-controlled parallel trial. Setting: Subjects were free-living. Blood sampling and distribution of yoghurts were administered at a local hospital. Subjects: Seventy-eight adult men and women with cholesterol levels of 3.9 ± 7.8 mmolaL (mean AE s.d., 5.4 AE 0.7). Interventions: Subjects consumed 500 mL of control yoghurt daily for two weeks. They were then randomly allocated to receive 500 mL per day of control yoghurt or of yoghurt enriched with Lactobacillus acidophilus L-1 for another six weeks. The yoghurts were spiked with a trace of lithium; compliance as assessed by plasma lithium was excellent. Results: Energy and nutrient intake was constant, and identical for the two groups. Mean body weight was stable. Baseline blood lipid concentrations in the control and treatment groups were highly similar. The effect of consumption of Lactobacillus acidophilus L-1 vs control on total cholesterol was 70.02 mmolaL (95% CI, 70.18 ± 0.15) after three weeks and 0.04 mmolaL (95% CI, 70.12 ± 0.20) after six weeks. Serum LDL and HDLcholesterol and triacylglycerol levels were also unaffected. Conclusions: Yoghurt enriched with Lactobacillus acidophilus L-1 does not lower serum cholesterol in men and women with normal to borderline high cholesterol levels.
Introduction
The potential bene®cial effects of the so-called`probiotic' bacteria has raised much interest (Fuller, 1989; Orrhage et al, 1995; Saxelin, 1997) with cholesterol-lowering as a focus of research (Agerbñk et al, 1995; Richelsen et al, 1996; Lin et al, 1989; Schaafsma et al, 1998; Mital & Garg, 1995) . Commercial products with Lactobacillus acidophilus that claim to lower serum cholesterol are marketed by several major dairy companies in Europe (Anonymous, 1996) . However, this claim is mainly based on in vitro and animal studies. Several Lactobacillus acidophilus strains of human origin are able to remove cholesterol from culture media during growth in the presence of bile (Buck & Gilliland, 1994; Gilliland et al, 1985; Walker & Gilliland, 1993) . The mechanism of action is probably that the bacteria deconjugate bile acids which, when deconjugated, coprecipitate with cholesterol at a pH`5.5 (Gilliland et al, 1985; Klaver & Van der Meer, 1993; Tahri et al, 1995) . If this also occurs in vivo, such coprecipitation might increase faecal excretion of bile acids and cholesterol. It is thought that the liver will compensate for the loss of bile acids by converting cholesterol into new bile acids. This conversion of cholesterol into bile acids might lower serum cholesterol levels.
Evidence for a serum cholesterol lowering effect of Lactobacillus acidophilus in humans is sparse. Lin et al, 1989 found a cholesterol lowering effect of a mixture of Lactobacillus acidophilus and Lactobacillus bulgaricus in a 16-week parallel, placebo-controlled pilot trial with 38 subjects, but no effect in a subsequent 15-week double blind, cross-over trial with 344 subjects (Lin et al, 1989) . Consumption of yoghurt with Lactobacillus acidophilus in a cross-over study with 30 healthy men resulted in 4.4% lower mean cholesterol concentrations than consumption of a placebo (Schaafsma et al, 1998) .
We investigated whether Lactobacillus acidophilus lowered serum cholesterol in a placebo-controlled, doubleblind study with healthy volunteers. We chose volunteers with normal to borderline-high serum cholesterol levels because this is the target group for these yoghurts and because most dietary components that can lower serum cholesterol do so also in normocholesterolaemic subjects (Lu et al, 1997; Pelletier et al, 1995) . We chose a treatment period of six weeks because the same period or shorter was chosen in previous studies (Agerbñk et al, 1995; Lin et al, 1989; Schaafsma et al, 1998) . To our knowledge every dietary component that lowers cholesterol does so within six weeks. We chose the maximum dose that could be given in a yoghurt.
Subjects and methods
Prior approval for this study was obtained from the Medical Ethical Committee of the Department of Human Nutrition, Wageningen Agricultural University. All volunteers gave their written informed consent. Volunteers who completed the study received a ®nancial reward.
Subjects
Eligible for the study were healthy men and women between 18 and 65 y old who were free of heart disease, diabetes, liver or kidney disease, and did not use any medications known to affect blood lipid metabolism. Ninety-nine volunteers were screened and 85 were enrolled. Volunteers with a serum total cholesterol concentration higher than 8 mmolaL or a triacylglycerol concentration higher than 4 mmolaL were excluded. We made sure that at least 50% of the enrolled volunteers had serum cholesterol levels over 5 mmolaL, the cut-off value for mild hypercholesterolaemia in the Netherlands (Anonymous, 1992) . Three subjects dropped out because of vacations, two because of illness, one because she could not eat all the yoghurt and one because of gastrointestinal complaints. The study was completed by 39 subjects in each of the two test groups.
Study design
After a two-week run-in period, in which the subjects added 500 mL of control yoghurt to their daily diet, subjects were strati®ed according to sex, age and LDL-cholesterol. Subjects in each stratum were randomly allocated to receive either control or Lactobacillus acidophilus yoghurt for six weeks. Venous blood samples were taken after an overnight fast at the end of the run-in period and at three and six weeks after the start of the test-period. Blood samples were taken twice in each week at an interval of 2 ± 4 d, which amounted to a total of six blood samples during the study.
Yoghurts
The control yoghurt was a non-fat yoghurt with a starter culture of Streptococcus thermophilus. The test yoghurt was control yoghurt enriched with Lactobacillus acidophilus L-1. The yoghurt was made once a week (NIZO, the Netherlands) and was given fresh, not pasteurised. Subjects were instructed to take 200 mL of the yoghurt directly after breakfast and 300 mL directly after dinner.
Samples of both yoghurts were analysed on Rogosa medium every week. Levels of Lactobacillus acidophilus ranged from 4.8 6 10 9 to 2.7 6 10 10 colony forming units per 500 mL.
Measurements
Blood samples were allowed to clot at room temperature and were centrifuged for 10 min at 1500 6 g. Serum samples were stored at 780 C. Serum lipids were measured or computed as described previously (Siedel et al, 1983; Warnick et al, 1982; Sullivan et al, 1985) , with an intra-run coef®cient of variance of 2.6% and an inter-run coef®cient of variance of 3.8%.
Body weight was measured with subjects clothed but without shoes. We used a single 24 h recall method to estimate energy and macronutrient intake in all subjects.
Compliance Lithium chloride (250 mmol) was added to the yoghurt (500 mL) as a marker (Sanchez-Castillo et al, 1987) . Toxic effects of lithium below the therapeutic dose have not been reported (Amdisen, 1977; Lehmann, 1994) . The two serum samples of week three were pooled for lithium analysis, and so were the two samples of week six.
Serum samples were deproteinised by mixing ®ve parts with one part of 20% (wav) trichloroacetic acid. Lithium concentrations in deproteinised serum samples were measured by atomic absorption spectrophotometry (Miller et al, 1989) .
Subjects recorded missed supplements, illness, and use of medications in a diary.
Statistical analyses
The two-sample t-test was used to compare changes in the acidophilus group with changes in the control group.
Results
Each of the two test groups consisted of 11 men and 28 women with a mean age of 40 y and on average normal body weights and serum cholesterol values (Table 1) .
Blood lipid concentrations remained stable in the control group and were unaffected by consumption of Lactobacillus acidophilus L-1 ( Table 2 ). The net effect of consumption of Lactobacillus acidophilus L-1, computed as the difference in change in blood lipid concentrations between acidophilus group and control group, was close to zero (Figure 1 ). We did not perform separate analyses for men and women because our study was not designed to do this. Mean changes in blood lipids, however, were almost identical in men and women.
Twenty-one subjects in the control group and 21 subjects in the acidophilus group had initial serum cholesterol levels greater than 5.2 mmolaL (200 mgadL, mean 5.7 AE 0.4 mmolaL), the cut-off value for borderline high blood cholesterol in the USA (Anonymous, 1993) . Lactobacillus acidophilus had no effect on serum cholesterol levels in this subgroup either: the net effect on total cholesterol was an elevation of 0.01 mmolaL (95% CI, 70.19± 0.21) after three weeks and 0.08 mmolaL (95% CI, 70.12± 0.29) after six weeks. Effects on other blood lipids were even smaller (data not shown).
Changes in body weight were negligible; the mean difference in weight change between the acidophilus and control group was 0.04 kg (95% CI, 70.37± 0.44) at week three and 0.21 kg (95% CI, 70.35± 0.78) at week six. 
Lactobacillus acidophilus L-1 does not lower blood lipids NM de Roos et al
Mean intake of total energy, macronutrients, ®bre and cholesterol as measured by 24 h recall was not different between the test groups.
Compliance, de®ned as a rise in serum lithium of at least three times the baseline value, was excellent. Mean serum lithium levels at three and six weeks were about 6.5-fold higher than baseline values. Two subjects from the acidophilus group had an increase from baseline of less than a factor three: one of them at week three and six, the other only at week six. Excluding these subjects from the analysis did not affect the outcome of the study.
Discussion
Lactobacillus acidophilus is the best studied of the`probiotic' cholesterol-lowering bacteria (Lin et al, 1989; Schaafsma et al, 1998; Harrison & Peat, 1975; Khedkar et al, 1993; de Rodas et al, 1996) . Of all the Lactobacillus acidophilus-strains the L-1 strain, used in commercial products in the Netherlands, is thought to be one of the most effective strains to lower serum cholesterol (Buck & Gilliland, 1994) . Our study, however, shows that daily consumption of yoghurt enriched with a high dose of Lactobacillus acidophilus L-1 for a period of six weeks does not lower blood lipid concentrations in men and women with normal to borderline high serum cholesterol levels. The 95% con®dence intervals for the net effect of the acidophilus yoghurt on serum LDL levels make any change of more than 0.15 mmolaL (4.7%) unlikely.
The compliance of the subjects, checked by addition of a trace of lithium to the yoghurts, was excellent. Weight changes were negligible and background food intake was the same for the two groups.
Choice of subjects with normal to borderline high serum cholesterol levels We do not think that the absence of an effect of the Lactobacillus acidophilus in our study was due to low initial cholesterol levels in our subjects. Feeding studies with fatty acids (Lu et al, 1997; Perez-Jimenez et al, 1995; Abbey et al, 1994; Cobb & Risch, 1993; Chan et al, 1991) , fat restriction (Lefevre et al, 1997; Jenkins et al, 1997; Miller et al, 1998; Schaefer et al, 1995) , psyllium (Ganji & Kies, 1996) , or phytosterols (Pelletier et al, 1995) , have shown that serum total cholesterol can be reduced in subjects with comparable or even lower mean serum cholesterol levels. Also, the subgroup with a mean total cholesterol level of 5.7 mmolaL (220 mgadL) did not respond to Lactobacillus acidophilus either. It is unlikely that patients with borderline high blood cholesterol will bene®t from consumption of Lactobacillus acidophilus.
Choice and dosage of probiotic strain It is possible that the strain we used in our study is not the most potent strain for cholesterol reduction. However, the strain used in this present study had the highest ability to remove cholesterol from a medium in vitro (Buck & Gilliland, 1994; Gilliland et al, 1985; Walker & Gilliland, 1993) .
The dose we gave, 10 9 ± 10 10 colony-forming units per day, was up to 1000 times higher than that of previous studies aimed at cholesterol-lowering (Agerbñk et al, 1995; Lin et al, 1989; Schaafsma et al, 1998; Harrison & Peat, 1975; Khedkar et al, 1993) . It is not possible to incorporate larger amounts into yoghurts or similar foods.
Length of treatment period
After a run-in period of two weeks we measured serum cholesterol after three and six weeks of treatment to measure short-term as well as long-term effects. Although we cannot exclude an effect of Lactobacillus acidophilus after a longer treatment period, we are not aware of any dietary component that has no effect for up to six weeks and then starts to lower serum cholesterol after more than six weeks.
The hypothesis for the cholesterol lowering effect of Lactobacillus acidophilus L-1 is based on its ability to deconjugate bile acids in vitro. At a pH lower than 5.5 deconjugated bile acids and cholesterol coprecipitate and are excreted in faeces (Klaver & Van der Meer, 1993) . However, the neutral to alkaline pH of the small intestine makes precipitation of cholesterol and deconjugated bile acids in vivo unlikely. Indeed, consumption of a fermented dairy product containing Lactobacillus acidophilus did not increase the relative amount of deconjugated bile salts in faeces of 8 ileostomy patients (Marteau et al, 1995) . Lactobacillus acidophilus L-1 does not lower blood lipids NM de Roos et al
Conclusions
Yoghurt containing Lactobacillus acidophilus strain L-1 did not lower blood lipids in men and women with normal and borderline high blood cholesterol. Claims to such an effect would not be justi®ed. More in general, claims made by commercial producers that probiotic yoghurts lower serum cholesterol in man should not be based solely on in vitro and animal studies but should be supported by proper randomised trials in man.
